亚辉龙(688575) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 431,322,575.83, representing a decrease of 34.65% compared to the same period last year[15]. - The net profit attributable to shareholders of the listed company was CNY 66,034,591.72, down 18.72% year-on-year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 57,166,617.62, a decrease of 31.29% compared to the previous year[15]. - In Q1 2024, the company achieved operating revenue of RMB 431.32 million, a decrease of 34.65% year-on-year; net profit attributable to shareholders was RMB 66.03 million, down 18.72% year-on-year[26]. - Net profit attributable to shareholders of the listed company fell by 18.71%, primarily due to a decline in COVID-related business revenue[42]. - The net profit excluding non-recurring gains and losses decreased by 31.28%[42]. - The total profit for the period was 63,495,903.50, compared to 83,360,612.59 in the previous year[57]. - The net profit for the period was 55,939,738.75, down from 67,743,836.57 in the previous year[57]. - Basic earnings per share for the period were 0.12, compared to 0.14 in the previous year[41]. - The company's total operating profit for Q1 2024 was RMB 64,004,346.42, down from RMB 84,505,378.51 in Q1 2023[63]. Assets and Equity - The total assets at the end of the reporting period were CNY 3,862,261,571.05, an increase of 1.48% from the end of the previous year[17]. - The equity attributable to shareholders of the listed company was CNY 2,626,037,203.18, reflecting a 2.59% increase from the previous year[17]. - The total liabilities and shareholders' equity amounted to 3,862,261,571.05, compared to 3,806,083,365.13 in the previous year[36]. - The company's total equity attributable to shareholders was 2,626,037,203.18, an increase from 2,559,840,879.62 in the previous year[36]. - The total assets of the company as of March 31, 2024, amounted to RMB 3.86 billion, compared to RMB 3.81 billion at the end of 2023[35]. Cash Flow - The net cash flow from operating activities was CNY 70,007,095.70[17]. - Net cash flow from operating activities for Q1 2024 was RMB 70,007,095.70, a significant improvement from a negative RMB 361,704,844.36 in Q1 2023[65]. - Cash and cash equivalents at the end of Q1 2024 were RMB 502,908,916.24, compared to RMB 726,160,578.88 at the end of Q1 2023[66]. - The company reported a net loss from investments of RMB 5,549,342.37 in Q1 2024, contrasting with a gain of RMB 1,718,670.02 in Q1 2023[63]. - Total cash inflow from investment activities in Q1 2024 was RMB 62,563,900.46, compared to RMB 50,247,072.08 in Q1 2023[66]. - The company’s financing activities generated a net cash inflow of RMB 35,735,837.11 in Q1 2024, compared to a net outflow of RMB 11,698,643.72 in Q1 2023[66]. Research and Development - Research and development expenses totaled CNY 84,553,036.69, which is 19.60% of operating revenue, an increase of 10.18 percentage points year-on-year[17]. - Research and development expenses increased to RMB 83,803,207.87 in Q1 2024, up 40.4% from RMB 59,637,893.36 in Q1 2023[63]. Business Operations - Non-COVID self-operated business revenue reached RMB 341.68 million in Q1 2024, representing a year-on-year growth of 43.33%[27]. - Domestic non-COVID self-operated business revenue was RMB 302.99 million, up 44.10% year-on-year, with domestic self-produced chemiluminescence business revenue at RMB 273.69 million, a 47.73% increase[28]. - As of March 31, 2024, the company’s products covered over 5,440 domestic terminal medical institutions, an increase of over 150 from the end of 2023, with coverage in over 1,180 tertiary hospitals[29]. - In Q1 2024, the company installed 418 new self-produced chemiluminescence analyzers, with 271 units in the domestic market and 147 units overseas[48]. - The company has obtained 157 domestic medical device registration certificates for chemiluminescence reagents, enhancing its product offerings in reproductive health diagnostics[48]. Operating Costs - Total operating costs for Q1 2024 were RMB 375,490,702.93, down 34.0% from RMB 567,935,779.01 in Q1 2023[63]. - Sales revenue from goods and services received cash of RMB 449,418,964.34 in Q1 2024, an increase from RMB 403,448,280.82 in Q1 2023[65].